Trumenba Vaccine + MenACWY Vaccine
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gonorrhea
Conditions
Gonorrhea, Chlamydia, Meningococcal Vaccines
Trial Timeline
Apr 24, 2023 → Mar 31, 2024
NCT ID
NCT05873751About Trumenba Vaccine + MenACWY Vaccine
Trumenba Vaccine + MenACWY Vaccine is a pre-clinical stage product being developed by Pfizer for Gonorrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT05873751. Target conditions include Gonorrhea, Chlamydia, Meningococcal Vaccines.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05873751 | Pre-clinical | Completed |
Competing Products
2 competing products in Gonorrhea
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| solithromycin + ceftriaxone + azithromycin | Allergy Therapeutics | Phase 3 | 72 |
| Doxycycline Hyclate Delayed-Release 200 mg | Mayne Pharma Group | Approved | 77 |